Peptidase neurolysin functions to preserve the brain after ischemic stroke in male mice
- 5 September 2019
- journal article
- research article
- Published by Wiley in Journal of Neurochemistry
- Vol. 153 (1), 120-137
- https://doi.org/10.1111/jnc.14864
Abstract
Previous studies documented up‐regulation of peptidase neurolysin (Nln) after brain ischemia, however, the significance of Nln function in the post‐stroke brain remained unknown. The aim of this study was to assess the functional role of Nln in the brain after ischemic stroke. Administration of a specific Nln inhibitor Agaricoglyceride A (AgaA) to mice after stroke in a middle cerebral artery occlusion model, dose‐dependently aggravated injury measured by increased infarct and edema volumes, blood–brain barrier disruption, increased levels of interleukin 6 and monocyte chemoattractant protein‐1, neurological and motor deficit 24 h after stroke. In this setting, AgaA resulted in inhibition of Nln in the ischemic hemisphere leading to increased levels of Nln substrates bradykinin, neurotensin, and substance P. AgaA lacked effects on several physiological parameters and appeared non‐toxic to mice. In a reverse approach, we developed an adeno‐associated viral vector (AAV2/5‐CAG‐Nln) to overexpress Nln in the mouse brain. Applicability of AAV2/5‐CAG‐Nln to transduce catalytically active Nln was confirmed in primary neurons and in vivo. Over‐expression of Nln in the mouse brain was also accompanied by decreased levels of its substrates. Two weeks after in vivo transduction of Nln using the AAV vector, mice were subjected to middle cerebral artery occlusion and the same outcome measures were evaluated 72 h later. These experiments revealed that abundance of Nln in the brain protects animals from stroke. This study is the first to document functional significance of Nln in pathophysiology of stroke and provide evidence that Nln is an endogenous mechanism functioning to preserve the brain from ischemic injury.Keywords
Funding Information
- American Heart Association (14BGIA20380826)
- National Institutes of Health (1R01NS106879)
This publication has 63 references indexed in Scilit:
- Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemiaJournal of Neuroinflammation, 2012
- Identification of Membrane-bound Variant of Metalloendopeptidase Neurolysin (EC 3.4.24.16) as the Non-angiotensin Type 1 (Non-AT1), Non-AT2 Angiotensin Binding SiteOnline Journal of Public Health Informatics, 2012
- Stroke research at a crossroad: asking the brain for directionsNature Neuroscience, 2011
- Kinin Receptor Antagonists as Potential Neuroprotective Agents in Central Nervous System InjuryMolecules, 2010
- Preliminary biochemical characterization of the novel, non-AT1, non-AT2 angiotensin binding site from the rat brainEndocrine, 2010
- Inhibition of Bradykinin Receptor B1 Protects Mice from Focal Brain Injury by Reducing Blood–Brain Barrier Leakage and InflammationJournal of Cerebral Blood Flow & Metabolism, 2010
- The Role of Bradykinin B1 and B2 Receptors for Secondary Brain Damage after Traumatic Brain Injury in MiceJournal of Cerebral Blood Flow & Metabolism, 2009
- Comparison of transduction efficiency of recombinant AAV serotypes 1, 2, 5, and 8 in the rat nigrostriatal systemJournal of Neurochemistry, 2009
- Human brain contains a novel non-AT1, non-AT2 binding site for active angiotensin peptidesLife Sciences, 2008
- Novel Analgesic Triglycerides from Cultures of Agaricus macrosporus and Other Basidiomycetes as Selective Inhibitors of NeurolysinThe Journal of Antibiotics, 2005